Hims & Hers Health Stock Plummets Amid Weak Guidance and Regulatory Scrutiny
Hims & Hers Health (HIMS) shares tumbled 6.4% in premarket trading following a disappointing Q1 revenue forecast and regulatory concerns. The telehealth company reported Q4 revenue of $617.8 million, narrowly missing analyst expectations, while adjusted EPS of $0.08 surpassed estimates.
The company's Q1 2026 revenue guidance of $600-$625 million fell significantly short of Wall Street's $653 million projection. Regulatory pressures intensified as the FDA referred Hims to the Justice Department for potential violations of the Food, Drug, and Cosmetic Act.
Year-to-date, HIMS stock has lost more than half its value, battered by Novo Nordisk lawsuits and mounting regulatory challenges. The weak outlook overshadowed what might have been interpreted as a respectable quarterly performance in less turbulent times.
